

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Botanix Pharmaceuticals Limited
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Vincent Ippolito
<b>Date of last notice</b>	04/01/2023

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Ippolito is a trustee of the Ippolito Trust
<b>Date of change</b>	20/03/2023
<b>No. of securities held prior to change</b>  Vincent Peter Ippolito   Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust>	6,801,644 Ordinary Shares  12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023  6,000,000 Performance rights  3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
<b>Class</b>	Ordinary Shares Performance Rights
<b>Number acquired</b>	2,000,000 Ordinary Shares
<b>Number disposed</b>	2,000,000 Performance Rights

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after the change</b>  Vincent Peter Ippolito    Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust>	8,801,644 Ordinary Shares  12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023  4,000,000 Performance rights  3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights

## Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Botanix Pharmaceuticals Limited
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Matthew Callahan
<b>Date of last notice</b>	04/01/2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Shenasaby Pty Ltd < Shenasaby Trust> (Mr Callahan is a beneficiary of this trust)
<b>Date of change</b>	20/03/2023
<b>No. of securities held prior to change</b>	Shenasaby Pty Ltd < Shenasaby Trust> 72,253,458 Ordinary Shares 3,500,000 Performance Rights
<b>Class</b>	Ordinary Shares Performance Rights
<b>Number acquired</b>	1,166,666 Ordinary Shares
<b>Number disposed</b>	1,166,666 Performance Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	Shenasaby Pty Ltd < Shenasaby Trust> 73,420,124 Ordinary Shares 2,333,334 Performance Rights

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights
---	--------------------------------

## Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Botanix Pharmaceuticals Limited
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr H. William Bosch
<b>Date of last notice</b>	04/01/2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	
<b>Date of change</b>	20/03/2023
<b>No. of securities held prior to change</b>	17,836,702 Ordinary Shares 1,500,000 Performance Rights
<b>Class</b>	Ordinary Shares Performance Rights
<b>Number acquired</b>	500,000 Ordinary Shares
<b>Number disposed</b>	500,000 Performance Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	18,336,702 Ordinary Shares 1,000,000 Performance Rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights

## Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Botanix Pharmaceuticals Limited</b>
<b>ACN</b>	<b>009 109 755</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Stewart Washer
<b>Date of last notice</b>	04/01/2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (Including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust (Dr Washer is a trustee and beneficiary of the trust) Mal Washer Nominees Pty Ltd (Dr Washer is a director of the company)

<b>Date of change</b>	20/03/2023
<b>No. of securities held prior to change</b>  Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust  Mal Washer Nominees Pty Ltd	321,551 Ordinary Shares 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025 1,000,000 Performance Rights  1,515,151 Ordinary Shares
<b>Class</b>	Ordinary Shares Performance Rights

+ See chapter 19 for defined terms.

<b>Number acquired</b>	333,333 Ordinary Shares
<b>Number disposed</b>	333,333 Performance Rights
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>  Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust   Mal Washer Nominees Pty Ltd	654,884 Ordinary Shares 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025 666,667 Performance Rights  1,515,151 Ordinary Shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Exercise of Performance Rights

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.



**Part 3 Closed Period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Botanix Pharmaceuticals Limited</b>
<b>ACN</b>	<b>009 109 755</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Daniel Sharp
<b>Date of last notice</b>	04/01/2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	DJMB Corporate Pty Ltd (Mr Sharp is a director of DJMB Corporate Pty Ltd)
<b>Date of change</b>	20/3/2023
<b>No. of securities held prior to change</b>  DJMB Corporate Pty Ltd	1,515,151 Ordinary Shares  1,000,000 Unlisted Options exercisable at 0.071 each, expiring 22 March 2022  4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 and vesting progressively over three years  1,000,000 Performance Rights
<b>Class</b>	Ordinary Shares Performance Rights Unlisted Options

+ See chapter 19 for defined terms.

<b>Number acquired</b>	616,162 Ordinary Shares
<b>Number disposed</b>	333,333 Performance Rights 1,000,000 Unlisted Options exercisable at 0.071 each, expiring 22 March 2022
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>  DJMB Corporate Pty Ltd	2,131,313 Ordinary Shares  4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 and vesting progressively over three years  666,667 Performance Rights
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Exercise of Performance Rights and Unlisted Options

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

## Part 3 Closed Period

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

+ See chapter 19 for defined terms.